Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an update.
Recce Pharmaceuticals Ltd announced the availability of a recording from their recent investor webinar, where company executives discussed updates on clinical activities and the outlook for upcoming Phase 3 trials. They also detailed a recent AUD ~$15.8 million Placement and Entitlement Offer, which will support their clinical activities as they move towards commercialization in 2026.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a leading developer in the pharmaceutical industry, focusing on creating a new class of synthetic anti-infectives. The company is dedicated to advancing its innovative treatments towards commercialization, with a market focus on addressing infectious diseases.
YTD Price Performance: -39.58%
Average Trading Volume: 207,432
Technical Sentiment Signal: Buy
Current Market Cap: A$78.45M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue